Katherine R Sabourin1,2, Ibrahim Daud3, Sidney Ogolla3, Nazzarena Labo4, Wendell Miley4, Molly Lamb1, Robert Newton5, Denise Whitby4, Rosemary Rochford2. 1. Department of Epidemiology, Colorado School of Public Health, Denver, Colorado, USA. 2. Department of Immunology and Microbiology, University of Colorado, Denver, Colorado, USA. 3. Centre for Global Health Research, Kenya Medical Research Institute, Kisumu, Kenya. 4. Frederick National Laboratory for Cancer Research, Leidos Biomedical Research, Frederick, Maryland, USA. 5. Department of Health Sciences, University of York, York, United Kingdom.
Abstract
BACKGROUND: We aimed to determine whether Plasmodium falciparum infection affects age of Kaposi sarcoma-associated herpesvirus (KSHV) seroconversion in Kenyan children. METHODS: Kenyan children (n = 144) enrolled at age 1 month, from 2 sites with different levels of malaria transmission (stable/high vs unstable/low) were followed to age 24 months. Plasma was tested for KSHV antibodies using enzyme-linked immunosorbent assay (ELISA; K8.1 and LANA) and a multiplex bead-based assay (K8.1, K10.5, ORF38, ORF50, and LANA) and whole blood tested for P. falciparum DNA using quantitative PCR. Cox proportional hazards models were used to assess associations between P. falciparum DNA detection, malaria annualized rate (P. falciparum detections/person-years), and enrollment site (malaria-high vs malaria-low) with time to KSHV seroconversion. RESULTS: KSHV seroprevalence was 63% by age 2 years when assessed by multiplex assay. Children with P. falciparum were at increased hazards of earlier KSHV seroconversion and, among children with malaria, the hazard of becoming KSHV seropositive increased significantly with increasing malaria annualized rate. Children from the malaria-high transmission region had no significant difference in hazards of KSHV seroconversion at 12 months but were more likely to become KSHV seropositive by age 24 months. DISCUSSION: Malaria exposure increases the risk for KSHV seroconversion early in life.
BACKGROUND: We aimed to determine whether Plasmodium falciparum infection affects age of Kaposi sarcoma-associated herpesvirus (KSHV) seroconversion in Kenyan children. METHODS: Kenyan children (n = 144) enrolled at age 1 month, from 2 sites with different levels of malaria transmission (stable/high vs unstable/low) were followed to age 24 months. Plasma was tested for KSHV antibodies using enzyme-linked immunosorbent assay (ELISA; K8.1 and LANA) and a multiplex bead-based assay (K8.1, K10.5, ORF38, ORF50, and LANA) and whole blood tested for P. falciparum DNA using quantitative PCR. Cox proportional hazards models were used to assess associations between P. falciparum DNA detection, malaria annualized rate (P. falciparum detections/person-years), and enrollment site (malaria-high vs malaria-low) with time to KSHV seroconversion. RESULTS: KSHV seroprevalence was 63% by age 2 years when assessed by multiplex assay. Children with P. falciparum were at increased hazards of earlier KSHV seroconversion and, among children with malaria, the hazard of becoming KSHV seropositive increased significantly with increasing malaria annualized rate. Children from the malaria-high transmission region had no significant difference in hazards of KSHV seroconversion at 12 months but were more likely to become KSHV seropositive by age 24 months. DISCUSSION: Malaria exposure increases the risk for KSHV seroconversion early in life.
Authors: Georgina L Mbisa; Wendell Miley; Christine J Gamache; William K Gillette; Dominic Esposito; Ralph Hopkins; Michael P Busch; George B Schreiber; Richard F Little; Robert Yarchoan; Betty A Ortiz-Conde; Nazzarena Labò; Denise Whitby Journal: J Immunol Methods Date: 2010-03-04 Impact factor: 2.303
Authors: Veenu Minhas; Brad P Brayfield; Kay L Crabtree; Chipepo Kankasa; Charles D Mitchell; Charles Wood Journal: BMC Infect Dis Date: 2010-05-12 Impact factor: 3.090
Authors: T A Reese; B S Wakeman; H S Choi; M M Hufford; S C Huang; X Zhang; M D Buck; A Jezewski; A Kambal; C Y Liu; G Goel; P J Murray; R J Xavier; M H Kaplan; R Renne; S H Speck; M N Artyomov; E J Pearce; H W Virgin Journal: Science Date: 2014-06-26 Impact factor: 47.728
Authors: Sam M Mbulaiteye; Ruth M Pfeiffer; Eric A Engels; Vickie Marshall; Paul M Bakaki; Anchilla M Owor; Christopher M Ndugwa; Edward Katongole-Mbidde; James J Goedert; Robert J Biggar; Denise Whitby Journal: J Infect Dis Date: 2004-09-10 Impact factor: 5.226
Authors: Ibironke Olofin; Christine M McDonald; Majid Ezzati; Seth Flaxman; Robert E Black; Wafaie W Fawzi; Laura E Caulfield; Goodarz Danaei Journal: PLoS One Date: 2013-05-29 Impact factor: 3.240